Amy D Shapiro

List of Publications by Year
in descending order

77 papers	5,738 citations	159585 30 h-index	74163 75 g-index
80 all docs	80 docs citations	80 times ranked	3259 citing authors

#	Article	IF	Citations
1	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	27.0	1,681
2	Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery. Thrombosis and Haemostasis, 1998, 80, 773-778.	3.4	365
3	A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 1994, 83, 2428-35.	1.4	305
4	Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift Mutation. New England Journal of Medicine, 1992, 327, 1729-1733.	27.0	274
5	Modern haemophilia care. Lancet, The, 2012, 379, 1447-1456.	13.7	266
6	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	4.6	252
7	Rare bleeding disorders: diagnosis and treatment. Blood, 2015, 125, 2052-2061.	1.4	244
8	Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene. Blood, 1997, 90, 204-208.	1.4	215
9	Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 2012, 119, 666-672.	1.4	167
10	VERITASâ€Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia, 2010, 16, 247-255.	2.1	104
11	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	30.5	103
12	A null mutation in SERPINE1 protects against biological aging in humans. Science Advances, 2017, 3, eaao1617.	10.3	95
13	Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia, 1999, 5, 101-105.	2.1	92
14	Clinical evaluation of recombinant factor IX. Seminars in Hematology, 1998, 35, 33-8.	3.4	88
15	The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood, 2005, 105, 518-525.	1.4	83
16	Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene. Blood, 1997, 90, 204-208.	1.4	70
17	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances, 2020, 4, 2451-2459.	5.2	67
18	Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia, 2005, 11, 571-582.	2.1	60

#	Article	IF	Citations
19	Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. Thrombosis and Haemostasis, 2008, 100, 217-223.	3.4	60
20	Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia, 2018, 24, 693-702.	2.1	60
21	The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. Journal of Thrombosis and Haemostasis, 2018, 16, 2362-2374.	3.8	50
22	Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two <scp>US</scp> centres. Haemophilia, 2015, 21, 365-373.	2.1	41
23	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A withÂinhibitorsâ€”A retrospective analysis. Haemophilia, 2018, 24, 245-252.	2.1	39
24	Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Realâ€world experience from a large comprehensive treatment centre in the US. Haemophilia, 2021, 27, 90-99.	2.1	37
25	Prevalence of elevated antithyroid antibodies and antinuclear antibodies in children with immune thrombocytopenic purpura. American Journal of Hematology, 2005, 79, 175-179.	4.1	34
26	Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opinion on Biological Therapy, 2013, 13, 1287-1297.	3.1	33
27	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the <scp>VERITAS</scp>â€Pro scale. Haemophilia, 2014, 20, 616-623.	2.1	32
28	Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vascular Health and Risk Management, 2007, 3, 555-65.	2.3	32
29	Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opinion on Biological Therapy, 2009, 9, 273-283.	3.1	31
30	Switching to recombinant factor <scp>IX</scp> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <scp>IX</scp> consumption and lower bleeding rates. British Journal of Haematology, 2015, 168, 113-123.	2.5	31
31	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 508-518.	3.4	31
32	The effects of joint disease, inhibitors and other complications on healthâ€related quality of life among males with severe haemophilia A in the United States. Haemophilia, 2017, 23, e287-e293.	2.1	28
33	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the Bâ€YOND extension study. Haemophilia, 2020, 26, e262-e271.	2.1	28
34	Safety and Efficacy of Monoclonal Antibody Purified Factor IX Concentrate in Previously Untreated Patients with Hemophilia B. Thrombosis and Haemostasis, 1996, 75, 030-035.	3.4	28
35	Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood, 2018, 131, 1301-1310.	1.4	27
36	Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia, 2016, 22, 419-425.	2.1	25

#	Article	IF	Citations
37	Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 97-104.	3.3	25
38	Variability of In Vivo Recovery of Factor IX after Infusion of Monoclonal Antibody Purified Factor IX Concentrates in Patients with Hemophilia B. Thrombosis and Haemostasis, 1995, 73, 779-784.	3.4	25
39	The use of prophylaxis in the treatment of rare bleeding disorders. Thrombosis Research, 2020, 196, 590-602.	1.7	23
40	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	2.1	21
41	Pharmacokinetics of a highâ€purity plasmaâ€derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia, 2016, 22, 426-432.	2.1	17
42	Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfusion and Apheresis Science, 2019, 58, 578-589.	1.0	17
43	Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Advances, 2021, 5, 279-279.	5.2	17
44	Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group. Transfusion, 1995, 35, 204-208.	1.6	16
45	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	1.8	15
46	U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors. Haemophilia, 2012, 18, 400-405.	2.1	14
47	Safety of recombinant activated factor VII (<scp>rFVII</scp>a) in patients with congenital haemophilia with inhibitors: overall <scp>rFVII</scp>a exposure and intervals following high (>240ÂÎ¼gÂkg^{âˆ'1}) <scp>rFVII</scp>a doses across clinical trials and registries. Haemophilia, 2014, 20, e23-31.	2.1	14
48	Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clinical Advances in Hematology and Oncology, 2008, 6, 579-86.	0.3	14
49	Why is primary prophylaxis underutilized in the United States?. Haemophilia, 2003, 9, 670-672.	2.1	13
50	Knowledge and Therapeutic Gaps. American Journal of Preventive Medicine, 2011, 41, S324-S331.	3.0	13
51	Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in women and girls with hereditary factor X deficiency. Journal of Thrombosis and Haemostasis, 2018, 16, 849-857.	3.8	13
52	An international registry of patients with plasminogen deficiency (HISTORY). Haematologica, 2020, 105, 554-561.	3.5	13
53	Realâ€world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5Âyears. Haemophilia, 2020, 26, 975-983.	2.1	12
54	Potential of the Community Counts registry to characterize rare bleeding disorders. Haemophilia, 2019, 25, 1045-1050.	2.1	11

#	Article	IF	Citations
55	The Bâ€Natural studyâ€"The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia, 2021, 27, 802-813.	2.1	11
56	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances, 2021, 5, 2732-2739.	5.2	11
57	BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood, 2018, 132, 636-636.	1.4	11
58	Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and nonâ€haemophilic patients. Haemophilia, 2018, 24, 807-814.	2.1	10
59	Integrated analysis of safety data from 12 clinical interventional studies of plasmaâ€and albuminâ€free recombinant factor VIII (r AHF â€PFM) in haemophilia A. Haemophilia, 2015, 21, 791-798.	2.1	9
60	Treatment of bleeding episodes with recombinant factor <scp>VIII</scp> Fc fusion protein in Aâ€<scp>LONG</scp> study subjects with severe haemophilia A. Haemophilia, 2017, 23, 392-399.	2.1	9
61	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	1.5	8
62	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1. JAMA Cardiology, 2021, 6, 841.	6.1	8
63	Therapeutic and technological advancements in haemophilia care: Quantum leaps forward. Haemophilia, 2022, 28, 77-92.	2.1	8
64	Safety of high doses of a monoclonal antibody-purified factor IX concentrate. American Journal of Hematology, 1995, 49, 92-94.	4.1	7
65	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
66	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq0 0 0 rgBT /Overlock 10	2.1	7
67	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). Haemophilia, 2021, 27, 49-59.	2.1	6
68	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. Haemophilia, 2021, 27, 19-25.	2.1	6
69	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€" Unmet needs remain. Haemophilia, 2022, 28, 453-461.	2.1	5
70	Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications?. Haemophilia, 2014, 20, e367-e371.	2.1	3
71	Adherence is a human behaviour, assessing it requires multimethod evaluation with validated measures: Comment on Guedes VG et al (2019). Haemophilia, 2020, 26, 934-936.	2.1	3
72	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2022, 28, .	2.1	3

#	Article	IF	Citations
73	A promising onâ€demand treatment option for bleeding events in haemophilia patients with inhibitors. Haemophilia, 2017, 23, 810-811.	2.1	2
74	Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease. Blood, 2010, 116, 237-237.	1.4	2
75	Long-term surveillance of HIV, HBV, and HCV infected patients. Annals of Hematology, 1994, 68, S87-S88.	1.8	1
76	Response to Gringeri etÂal.: â€˜recombinant fullâ€length factor VIII (FVIII) and extended halfâ€life FVIII products in prophylaxis â€“ new insight provided by pharmacokinetic modellingâ€™. Haemophilia, 2015, 21, e489-92.	2.1	1
77	Final Results of the Prospective ADVATEÂ® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII. Journal of Blood Medicine, 2021, Volume 12, 991-1001.	1.7	0